The impact of APOE and smoking history on cognitive function in older, long-term breast cancer survivors

Purpose This study aims to determine whether older breast cancer survivors score lower on neuropsychological tests compared to matched non-cancer controls and to test the hypotheses that survivors who were APOE epsilon 4 carriers would have the lowest cognitive performance but that smoking history would decrease the negative effect of epsilon 4 on cognition. Methods Female breast cancer survivors who had been diagnosed and treated at age 60 or older and were 5-15-year survivors (N = 328) and age and education matched non-cancer controls (N = 162) were assessed at enrollment and at 8-, 16-, and 24-month follow-ups with standard neuropsychological and psychological assessments. Blood for APOE genotyping was collected, and smoking history was assessed at enrollment. Participants were purposely recruited so that approximately 50% had a history of treatment with chemotherapy or no chemotherapy and approximately 50% had a smoking history. Results After adjusting for age, cognitive reserve, depression, and fatigue, breast cancer survivors scored significantly lower on all domains of cognitive function. A significant two-way interaction demonstrated that the negative effect of epsilon 4 on cognitive performance was stronger among survivors. A significant three-way interaction supported the hypothesis that smoking history had a protective effect on cognitive function in epsilon 4 carriers that was more pronounced in the controls than the survivors. Conclusions The results support the long-term cognitive impact of breast cancer diagnosis and treatments on older, disease-free survivors, particularly for epsilon 4 carriers. The results also emphasize the importance of assessing smoking history when examining APOE and cognition and are an example of the complex interactions of age, genetics, health behaviors, and disease history in determining cognitive function. Implications for Cancer Survivors These results help explain why only a subset of breast cancer survivors appear to be vulnerable to cognitive problems.